Cargo Halts CAR T Trial, Lays Off 50% of Workforce in Pipeline Reset

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a mid-stage trial of its lead program, firi-cel.